Sbi Pharmaceuticals Co., Ltd.

Cosmo Oil Co., Ltd.

Kochi University

Other

Tokyo Institute of Technology

Osaka City University

Neo Ala Co., Ltd.

Sbi Alapromo Co., Ltd.

National University Corporation Kochi University

Masahiro Ishizuka

Tohru Tanaka

Setsuko Miyanari

Naohisa Tachiya

Masao Kondo

Hideki Okada

Kiwamu Takahashi

Motowo Nakajima

Seiji Nishikawa

Keiji Inoue

Mai Higo

Naomi Aiba

Urara Ota

Takaya Suzuki

Shingo Kato

Fuminori Abe

Takuya Ishii

Sotaro Miyano

Hitoshi Kumagai

Fumio Hamada

Keitaro Watanabe

Shigeyuki Funada

Taro Shuin

Mutsuo Furihata

Masumi Takahashi

Shun-ichiro Ogura

Toshiyuki Ozawa

Nobuhiko Iki

Hitoshi Nakagawa

Yoshihiro Sugawa

Mitsuharu Hasegawa

Masayuki Tsuda

Shunichiro Ogura

Hideo Fukuhara

Kyoko Tsuchiya

Toyohisa Fujimoto

Yoshiyuki Hiraishi

Urara Oto

Atsuko Kamiya

Mika Morishita

Kuniyuki Morimoto

Ichiro Okura

Toshiaki Kamachi

Toshihiko Kuroiwa

Yoshinaga Kajimoto

Takahiro Masubuchi

The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.

Aqueous formulation containing 5-aminolevulinic acid or the like

A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I):R&#x2014;NHCHCOCHCHCOOR&#x2003;&#x2003;(I)wherein Rrepresents a hydrogen atom or an acyl group, and Rrepresents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Treatment agent and/or prophylactic agent for side effects of cancer drugs

The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Medicinal composition for promoting synthesis of protoporphyrin IX

The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid.

Photodynamic diagnostic agent and photobleaching inhibitor

It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.

Diagnostic agent for tumor

According to the present invention, a tumor diagnostic agent which carries out early stage detection, monitoring of therapeutic effect and prognostic diagnosis of all tumors The tumor diagnostic agent of the present invention is a tumor diagnostic agent comprising &#x3b4;-aminolevulinic acid represented by formula (I), a derivative thereof and a salt thereof:RRNCHCOCHCHCOR&#x2003;&#x2003;(I)wherein Rand Reach independently represents hydrogen, alkyl, acyl, alkoxycarbonyl, aryl or aralkyl; and Rrepresents hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, aryloxy, aralkyloxy or amino, which is used for diagnoses by measuring porphyrins in a sample collected from the inside or outside of the body after its administration.

A metal component absorption enhancer which enhances the absorption of at least one metal component selected from the elements belonging to groups 2 to 12 in the third to fourth periods when a plant grows. The metal component absorption enhancer contains 5-aminolevulinic acid or a derivative thereof represented by the following general formula (1), or a salt thereof as an active ingredient:RRNCHCOCHCHCOR&#x2003;&#x2003;(1) wherein Rand Reach independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; Rrepresents a hydroxyl group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group, and is used for performing a treatment with 0.001 to 20 ppm of the 5-aminolevulinic acid, the derivative thereof, or the salt thereof per each time.

Metal component absorption enhancer in plant

Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.

Method of detecting bladder cancer

To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) &#x3b4;-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination.RRNCHCOCHCHCOR&#x2003;&#x2003;(1)wherein Rand Reach independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and Rrepresents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.

Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases

The present invention is drawn to a method of inducing thymocyte proliferation in a vertebrate animal with an impaired immune system comprising administering &#x3b4;-aminolevulinic acid or a salt thereof every day in succession. The method further comprises administering at least one mineral.

Constitutional function-improving agents

The present invention is intended to provide an agent for treating male infertility which is highly effective to male infertility, and having few side effects. To achieve the object, an agent for treating male infertility comprising &#x3b4;-amino levulinic acid shown by general formula (1), its derivative or salt thereof:RRNCHCOCHCHCOR&#x2003;&#x2003;(1)[wherein Rand Rindependently represent a hydrogen atom, alkyl group, acyl group, alkoxycarbonyl group, aryl group, or aralkyl group; Rrepresents a hydroxy group, alkoxy group, acyloxy group, alkoxycarbonyloxy group, aryloxy group, aralkyloxy group or amino group]can be used.

Therapeutic agent for male sterility

A 5-aminolevulinic acid salt which is useful in fields of microorganisms, fermentation, animals, medicaments, plants and the like; a process for producing the same; a medical composition comprising the same; and a plant activator composition comprising the same.

5-aminolevulinic acid salt, process for producing the same and use thereof

To provide a polyphenol-content-increasing agent which increases the content of polyphenol in a plant. A polyphenol-content-increasing agent for plant, containing, as an active ingredient, a 5-aminolevulinic acid or a derivative thereof represented by the following formula (1): (Chem 1)RRNCHCOCHCHCOR&#x2003;&#x2003;(1)wherein Rand Reach independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; Rrepresents a hydroxyl group, an alkoxy group which may have a substituent, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group, or a salt thereof.

Polyphenol-content-increasing agent for plant

SULFONATED DERIVATIVES OF CYCLIC PHENOL SULFIDES, PROCESS FOR THE PREPARATION THEREOF, SEPARATING AND RECOVERING AGENTS CONTAINING CYCLIC PHENOL SULFIDES, METHODS FOR SEPARATION AND RECOVERY THEREWITH, AND DRUG COMPOSITIONS CONTAINING THE SULFIDES

Growing community of inventors

Tokyo, Japan

Masahiro Ishizuka